Potential Demant divestment raises competition concerns
The proposed acquisition of Demant’s Oticon Medical division by Cochlear has caused concern at the Australian Competition and Consumer Commission.
by christian bundgaard, translated by catherine brett
In a statement of issues, the Australian Competition and Consumer Commission. (ACCC) has raised concerns about Cochlear’s proposed acquisition of Oticon Medical.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
